Pre-clinical data on Novogen’s Cantrixil to be presented at two upcoming conferences

Novogen today announces that Professor Gil Mor MD PhD from Yale Medical School will be presenting pre-clinical data on the lead candidate product, Cantrixil, at two upcoming conferences.

The first is an oral presentation at the 62nd Society of Reproductive Investigation conference, March 25-28, Hilton San Francisco, CA. Professor Mor's presentation will focus on the pre-clinical efficacy studies that justified the Company's decision to progress Cantrixil into the clinic for the treatment of abdominal carcinomatosis.

The second is a late-breaking poster at the annual American Association for Cancer Research (AACR) conference, April 18-22, Pennsylvania Convention Center, Philadelphia, PA. The presentation will review mechanistic aspects of Cantrixil efficacy in ovarian cancer stem cells, and also detail in vivo data generated on Cantrixil in Yale's recurrent ovarian cancer carcinomatosis model that has informed the design of the Company's first-in-man clinical trial.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI-powered MRI predicts outcomes in prostate cancer